Navigation Links
Celsense, Inc Files FDA & EMEA Regulatory Submissions
Date:10/12/2009

FDA accepts Drug Master File and EMEA receives Active Substance Master File for Cell Sense in vivo imaging agent

Pittsburgh, PA (Vocus) October 12, 2009 -- Celsense, Inc. announced today it has reached a critical milestone in the push to market for its lead in vivo imaging reagent, Cell Sense CS-1000 (Cell Sense).

Celsense filed a Drug Master File (a “DMF”) with CBER earlier this year which the Agency has now accepted. An FDA Drug Master File provides key information about the quality of components, materials and manufacturing processes involved in producing medical devices and human drugs, including related products such as imaging reagents like Cell Sense. The main objective of a DMF is to support the filing and obtaining of Investigational New Drug Applications (INDs) by investigators incorporating the use of Cell Sense in their clinical trial.

Additionally, Celsense last week submitted an Active Substance Master File (ASMF) with the European Medicines Agency (EMEA) serving the same function within the European regulatory framework and assisting European investigators in similar fashion.

“Having these regulatory filings available for investigators to reference in their clinical testing applications is critical to the rapid and widespread adoption of our in vivo imaging reagents,” said Charlie O’Hanlon, company President and CEO.

Indeed, the company announced earlier this year that the company was one of the recipients on a 4-year $1.95M grant from the National Institutes of Health intended to fund the first studies to evaluate

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

1

GOOD

Page: 1 2 3

Related medicine news :

1. Pan-American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica; Company Files Request for Authorization
2. Profiles International Finds High Employee Utilization is One Key to Maximizing Productivity
3. Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report
4. Texas Doctor Files Case Pro Se in U.S. Supreme Court Against Insurance Giant on Integrity and Unethical Practices
5. Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders & Financiers at AdvaMed 2009
6. Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents
7. GENova files patent for new breast cancer treatment
8. Longevinex(R) Files Lawsuit Against ResveratrolBenefits.com, for False and Misleading Statements
9. US Farms, Inc. Files Trademark Application for Aloe365
10. Genova files patent for new prostate cancer treatment
11. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celsense, Inc Files FDA & EMEA Regulatory Submissions
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... the rights of victims injured by defective medical devices, is ... in the case of the Estate of Fred E. Taylor ... County (Port Orchard). A May 21, 2013, Bloomberg ... Surgical had acted like a “car dealership” in how it ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
(Date:5/21/2013)... 2013 The federal judge overseeing the ... lawsuits in U.S. District Court, Northern District of ... request from Plaintiffs’ Counsel to conduct Ex Parte interviews ... 17th Order grants that request, and sets forth procedures ... Wright Medical Technology, Inc., Conserve Hip Implant Products Liability ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... brain,s dopamine levels could point to more effective treatments ... -- Long-term changes in the brain,s dopamine-releasing machinery may ... say. , Dopamine is one of the brain,s major ... Bamford, of the University of Washington, Seattle, treated mice ...
... Skin Care and Frida,Kahlo Store are proud to announce the ... benefit of The Leukemia & Lymphoma Society. It,will take place ... Staten Island, New York, at 7:30 pm. This concert is ... with the solution,of health and social problems., The event ...
... leading global clinical,research organization, is pleased to announce that ... with CRO,s in Las Vegas, Nevada from April,14 to ... by,some of its executive team and employees. Chiltern will ... 2008 at 2:45 pm -- Track: Relationship Management ...
... to use iSEEK Medical Searchblade to optimize patient management ... ... 9 Physicians, nurses,physician assistants, pharmacists, and other clinicians searching for,medical ... Thanks to a new partnership between MedPage Today and iSEEK,the medical ...
... Peninsula Medical School, South West England, has found strong ... health of older people. , Two studies were conducted, ... Study of Ageing (ELSA). , The first study ... lived in urban areas across England. The study found ...
... April 9, 2008 Reflecting the,growing concern over ... in being able to afford a comfortable retirement,decreased ... in the 18 years of the,Retirement Confidence Survey(R)(RCS), ... of workers very confident about having enough money ...
Cached Medicine News:Health News:Researchers Define Mechanism of Methamphetamine Addiction 2Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 3Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 4Health News:Your neighborhood can affect your health 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 3Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 4
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009.  Gross profit was ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products: